PXYLP1

Summary

PXYLP1 (2-phosphoxylose phosphatase 1, HGNC:26303) is a protein-coding gene on chromosome 3q23, encoding 2-phosphoxylose phosphatase 1 (Q8TE99). Responsible for the 2-O-dephosphorylation of xylose in the glycosaminoglycan-protein linkage region of proteoglycans thereby regulating the amount of mature glycosaminoglycan (GAG) chains.

Enables phosphatase activity. Involved in chondroitin sulfate proteoglycan biosynthetic process and positive regulation of heparan sulfate proteoglycan biosynthetic process. Located in Golgi apparatus.

Source: NCBI Gene 92370 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_001037172

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26303
Approved symbol	PXYLP1
Name	2-phosphoxylose phosphatase 1
Location	3q23
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23751
Ensembl gene	ENSG00000155893
Ensembl biotype	protein_coding
OMIM	619732
Entrez	92370

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 22 protein_coding, 5 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000286353, ENST00000393010, ENST00000502783, ENST00000504264, ENST00000505013, ENST00000505502, ENST00000508812, ENST00000511968, ENST00000512457, ENST00000513007, ENST00000513528, ENST00000514263, ENST00000514680, ENST00000514880, ENST00000636601, ENST00000637579, ENST00000637751, ENST00000879101, ENST00000879102, ENST00000879103, ENST00000879104, ENST00000925230, ENST00000925231, ENST00000925232, ENST00000971913, ENST00000971914, ENST00000971915, ENST00000971916, ENST00000971917, ENST00000971918, ENST00000971919

RefSeq mRNA: 3 — MANE Select: NM_001037172 NM_001037172, NM_001282728, NM_152282

CCDS: CCDS3116, CCDS63797

Canonical transcript exons

ENST00000286353 — 6 exons

Exon	Start	End
ENSE00001023284	141279378	141279504
ENSE00002025423	141292268	141294924
ENSE00002048205	141231825	141231911
ENSE00003468577	141287314	141287453
ENSE00003480344	141260123	141260254
ENSE00003648560	141278342	141278500

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 99.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.0475 / max 104.4298, expressed in 1586 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
38874	7.5754	1570
38872	0.1689	76
38871	0.0944	37
38880	0.0750	29
38873	0.0676	24
38876	0.0201	3
38879	0.0178	4
38875	0.0162	4
38870	0.0122	2

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	99.36	gold quality
secondary oocyte	CL:0000655	98.67	gold quality
tibia	UBERON:0000979	98.55	gold quality
thymus	UBERON:0002370	98.34	gold quality
oocyte	CL:0000023	97.69	gold quality
cauda epididymis	UBERON:0004360	97.32	gold quality
seminal vesicle	UBERON:0000998	96.98	gold quality
cartilage tissue	UBERON:0002418	94.30	gold quality
caput epididymis	UBERON:0004358	93.99	gold quality
tendon of biceps brachii	UBERON:0008188	93.74	gold quality
cortical plate	UBERON:0005343	93.55	gold quality
left testis	UBERON:0004533	93.44	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.38	gold quality
endothelial cell	CL:0000115	93.30	gold quality
right testis	UBERON:0004534	93.09	gold quality
ileal mucosa	UBERON:0000331	92.57	gold quality
testis	UBERON:0000473	91.84	gold quality
calcaneal tendon	UBERON:0003701	91.47	gold quality
middle temporal gyrus	UBERON:0002771	90.59	gold quality
tendon	UBERON:0000043	90.50	gold quality
epithelial cell of pancreas	CL:0000083	89.73	gold quality
ventricular zone	UBERON:0003053	89.41	gold quality
layer of synovial tissue	UBERON:0007616	89.32	gold quality
embryo	UBERON:0000922	89.14	gold quality
ganglionic eminence	UBERON:0004023	89.14	gold quality
primary visual cortex	UBERON:0002436	88.86	gold quality
germinal epithelium of ovary	UBERON:0001304	88.78	gold quality
decidua	UBERON:0002450	88.55	gold quality
pigmented layer of retina	UBERON:0001782	88.20	gold quality
retina	UBERON:0000966	88.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

111 targeting PXYLP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-5582-3P	99.86	72.48	4221

Literature-anchored findings (GeneRIF, showing 1)

• this study describes the cloning of a human cDNA encoding a novel protein designated 2-phosphoxylose phosphatase capable of dephosphorylating this Xyl residue. (PMID:24425863)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pxylp1	ENSDARG00000040644
mus_musculus	Pxylp1	ENSMUSG00000043587
rattus_norvegicus	Pxylp1	ENSRNOG00000012480
drosophila_melanogaster	CG15385	FBGN0031397
caenorhabditis_elegans		WBGENE00014076

Paralogs (5): ACP3 (ENSG00000014257), ACP2 (ENSG00000134575), ACP4 (ENSG00000142513), FRA10AC1 (ENSG00000148690), ACP6 (ENSG00000162836)

Protein

Protein identifiers

2-phosphoxylose phosphatase 1 — Q8TE99 (reviewed: Q8TE99)

Alternative names: Acid phosphatase-like protein 2, Xylosyl phosphatase, epididymis luminal protein 124

All UniProt accessions (10): Q8TE99, A0A1B0GUH7, A0A1B0GWB5, B7Z3R9, B7Z4T2, D6R928, D6RDP0, D6RE60, D6RGE3, E9PDB7

UniProt curated annotations — full annotation on UniProt →

Function. Responsible for the 2-O-dephosphorylation of xylose in the glycosaminoglycan-protein linkage region of proteoglycans thereby regulating the amount of mature glycosaminoglycan (GAG) chains. Sulfated glycosaminoglycans (GAGs), including heparan sulfate and chondroitin sulfate, are synthesized on the so-called common GAG-protein linkage region (GlcUAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1-O-Ser) of core proteins, which is formed by the stepwise addition of monosaccharide residues by the respective specific glycosyltransferases. Xylose 2-O-dephosphorylation during completion of linkage region formation is a prerequisite for the initiation and efficient elongation of the repeating disaccharide region of GAG chains.

Subunit / interactions. Interacts with B3GAT3; the interaction increases the 2-phosphoxylose phosphatase activity of PXYLP1 during completion of linkage region formation in a B3GAT3-mediated manner.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Widely expressed. Strongly expressed in spleen, fetal liver, moderately in placenta, pancreas, kidney, thymus and colon.

Similarity. Belongs to the histidine acid phosphatase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TE99-1	1	yes
Q8TE99-2	2

RefSeq proteins (3): NP_001032249, NP_001269657, NP_689495 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000560	His_Pase_clade-2	Family
IPR029033	His_PPase_superfam	Homologous_superfamily
IPR050645	Histidine_acid_phosphatase	Family

Pfam: PF00328

Catalyzed reactions (Rhea), 1 shown:

• 3-O-[beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-2-O-P-Xyl]-L-seryl-[protein] + H2O = 3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + phosphate (RHEA:56512)

UniProt features (9 total): topological domain 2, active site 2, glycosylation site 2, chain 1, transmembrane region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TE99-F1	89.61	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 97 (nucleophile); 379 (proton donor)

Glycosylation sites (2): 305, 354

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1971475	Glycosaminoglycan-protein linkage region biosynthesis

MSigDB gene sets: 198 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, TAL1ALPHAE47_01, LHX3_01, BOYLAN_MULTIPLE_MYELOMA_D_DN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_AMINOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_CHONDROITIN_SULFATE_PROTEOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_GLYCOPROTEIN_METABOLIC_PROCESS, GOBP_HEPARAN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, GOBP_POSITIVE_REGULATION_OF_GLYCOPROTEIN_METABOLIC_PROCESS

GO Biological Process (4): glycosaminoglycan biosynthetic process (GO:0006024), positive regulation of heparan sulfate proteoglycan biosynthetic process (GO:0010909), chondroitin sulfate proteoglycan biosynthetic process (GO:0050650), positive regulation of proteoglycan biosynthetic process (GO:1902730)

GO Molecular Function (3): phosphatase activity (GO:0016791), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycosaminoglycan metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteoglycan biosynthetic process	2
aminoglycan biosynthetic process	1
glycosaminoglycan metabolic process	1
regulation of heparan sulfate proteoglycan biosynthetic process	1
heparan sulfate proteoglycan biosynthetic process	1
positive regulation of proteoglycan biosynthetic process	1
positive regulation of protein O-linked glycosylation	1
chondroitin sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
positive regulation of glycoprotein biosynthetic process	1
phosphoric ester hydrolase activity	1
binding	1
catalytic activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

740 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PXYLP1	GALP	Q9UBC7	936
PXYLP1	ARAF	P07557	932
PXYLP1	B3GAT3	O94766	743
PXYLP1	FAM20B	O75063	669
PXYLP1	ALG11	Q2TAA5	584
PXYLP1	EXTL2	Q9UBQ6	578
PXYLP1	B3GALT6	Q96L58	516
PXYLP1	B4GALT7	Q9UBV7	497
PXYLP1	EXT2	Q93063	483
PXYLP1	XYLT1	Q86Y38	464
PXYLP1	XYLT2	Q9H1B5	440
PXYLP1	MEOX2	P50222	433
PXYLP1	EXTL3	O43909	431
PXYLP1	TMEM196	Q5HYL7	421
PXYLP1	XYLB	O75191	413

IntAct

27 interactions, top by confidence:

A	B	Type	Score
PXYLP1	ADCY9	psi-mi:“MI:0914”(association)	0.500
PXYLP1	ADCY9	psi-mi:“MI:0915”(physical association)	0.500
HTR3B	TMEM223	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CHRNB2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
KLRC4	RAP1BL	psi-mi:“MI:0914”(association)	0.350
KLRC1	METTL15	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
C1orf54	AGRN	psi-mi:“MI:0914”(association)	0.350
HFE	PODXL	psi-mi:“MI:0914”(association)	0.350
CHRNE	PODXL	psi-mi:“MI:0914”(association)	0.350
KLRC2	CLGN	psi-mi:“MI:0914”(association)	0.350
LY86	PLXNB2	psi-mi:“MI:0914”(association)	0.350
PTCH1	PLXNB2	psi-mi:“MI:0914”(association)	0.350
INS	LAMA5	psi-mi:“MI:0914”(association)	0.350
GALNT10	PLXNA2	psi-mi:“MI:0914”(association)	0.350
PXYLP1	GNPTAB	psi-mi:“MI:0914”(association)	0.350
FURIN	RHOBTB3	psi-mi:“MI:0914”(association)	0.350
ADCY9	COX7A2L	psi-mi:“MI:0914”(association)	0.350
FURIN	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A12	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A7	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (39): PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), ADCY9 (Affinity Capture-MS), FURIN (Affinity Capture-MS), GNPTAB (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Two-hybrid), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS)

ESM2 similar proteins: A8E7N9, E9Q6D8, F4J2C8, O43173, O75072, P13671, P54631, P61131, P61134, P61135, P61644, P85857, Q02745, Q0IHQ9, Q11206, Q19187, Q23534, Q4G148, Q5FVM7, Q5MD89, Q5RCM7, Q5SP46, Q5ZKI6, Q60HG0, Q619N4, Q64689, Q66H78, Q68G12, Q6DE37, Q6DH46, Q6GX83, Q6KB55, Q70D51, Q80TN4, Q811M5, Q8BHA9, Q8R507, Q8RXE1, Q8TE99, Q91Y74

Diamond homologs: A6H757, Q09448, Q09451, Q09549, Q0IHQ9, Q19076, Q54P71, Q54P72, Q5R8C0, Q66H78, Q8BHA9, Q8TE99, Q9NPH0, Q6DH46, A6H730, P15309, Q54PR9, Q8CE08

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1521 predictions. Top by Δscore:

Variant	Effect	Δscore
3:141231907:GGGCG:G	donor_gain	1.0000
3:141231908:GGCGG:G	donor_gain	1.0000
3:141260117:TCACA:T	acceptor_loss	1.0000
3:141260118:CACA:C	acceptor_loss	1.0000
3:141260119:ACAGG:A	acceptor_loss	1.0000
3:141260120:CAG:C	acceptor_loss	1.0000
3:141260121:AGGAC:A	acceptor_loss	1.0000
3:141260122:GGAC:G	acceptor_gain	1.0000
3:141260250:GTTCT:G	donor_gain	1.0000
3:141260255:G:GG	donor_gain	1.0000
3:141278340:A:AG	acceptor_gain	1.0000
3:141278341:G:GA	acceptor_gain	1.0000
3:141278341:GTC:G	acceptor_gain	1.0000
3:141278341:GTCC:G	acceptor_gain	1.0000
3:141231908:GGCG:G	donor_gain	0.9900
3:141231909:GCG:G	donor_gain	0.9900
3:141231909:GCGG:G	donor_gain	0.9900
3:141231910:CGGTG:C	donor_loss	0.9900
3:141231911:GGTG:G	donor_loss	0.9900
3:141231912:G:C	donor_loss	0.9900
3:141231912:G:GG	donor_gain	0.9900
3:141231913:T:G	donor_loss	0.9900
3:141231914:G:GG	donor_loss	0.9900
3:141260121:A:AG	acceptor_gain	0.9900
3:141260121:AG:A	acceptor_gain	0.9900
3:141260122:G:GA	acceptor_gain	0.9900
3:141260122:GG:G	acceptor_gain	0.9900
3:141260122:GGA:G	acceptor_gain	0.9900
3:141260122:GGACA:G	acceptor_gain	0.9900
3:141260251:TTCT:T	donor_gain	0.9900

AlphaMissense

3180 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:141279438:G:T	R100M	1.000
3:141287426:T:A	C160S	0.999
3:141287427:G:C	C160S	0.999
3:141292399:A:C	S213R	0.999
3:141292401:T:A	S213R	0.999
3:141292401:T:G	S213R	0.999
3:141292670:G:A	C303Y	0.999
3:141278465:G:A	C68Y	0.998
3:141279432:G:T	G98V	0.998
3:141279438:G:C	R100T	0.998
3:141279439:G:C	R100S	0.998
3:141279439:G:T	R100S	0.998
3:141279485:T:A	C116S	0.998
3:141279485:T:C	C116R	0.998
3:141279486:G:A	C116Y	0.998
3:141279486:G:C	C116S	0.998
3:141287426:T:C	C160R	0.998
3:141287427:G:A	C160Y	0.998
3:141292501:T:C	C247R	0.998
3:141292820:T:C	L353P	0.998
3:141292898:A:C	D379A	0.998
3:141292898:A:T	D379V	0.998
3:141293021:G:C	R420P	0.998
3:141293065:T:A	C435S	0.998
3:141293066:G:C	C435S	0.998
3:141293101:T:A	C447S	0.998
3:141293102:G:C	C447S	0.998
3:141278464:T:A	C68S	0.997
3:141278465:G:C	C68S	0.997
3:141279425:C:A	R96S	0.997

dbSNP variants (sampled 300 via entrez): RS1000045846 (3:141288831 G>A), RS1000125232 (3:141240547 G>A), RS1000146448 (3:141271310 C>T), RS1000147214 (3:141276643 C>T), RS1000308327 (3:141265841 C>G), RS1000334426 (3:141259931 T>G), RS1000335897 (3:141241788 G>A), RS1000341660 (3:141258373 A>C), RS1000367070 (3:141259624 T>C), RS1000492664 (3:141240750 G>A), RS1000502000 (3:141254593 C>G,T), RS1000551925 (3:141283725 G>A), RS1000564175 (3:141235730 T>C), RS1000579601 (3:141236117 C>G), RS1000616426 (3:141265648 C>T)

Disease associations

OMIM: gene MIM:619732 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST000477_10	Cognitive performance	8.000000e-06
GCST000522_8	Height	8.000000e-08
GCST004620_136	Sum basophil neutrophil counts	2.000000e-11
GCST004626_30	Myeloid white cell count	1.000000e-11
GCST004629_55	Neutrophil count	4.000000e-11
GCST008152_24	Weight	6.000000e-08
GCST008156_35	Hip circumference adjusted for BMI	6.000000e-07
GCST008161_16	Waist circumference adjusted for body mass index	5.000000e-06
GCST008163_510	Height	5.000000e-15
GCST008163_546	Height	5.000000e-10
GCST009391_432	Metabolite levels	9.000000e-06
GCST90002407_411	White blood cell count	9.000000e-19

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0003926	neuropsychological test
EFO:0004833	neutrophil count
EFO:0005090	basophil count
EFO:0004338	body weight
EFO:0008039	BMI-adjusted hip circumference
EFO:0007789	BMI-adjusted waist circumference
EFO:0010384	phosphatidylcholine 38:2 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	6
trichostatin A	affects cotreatment, decreases expression, increases expression	3
Cyclosporine	decreases expression	3
sodium arsenite	decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression, increases methylation, affects methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	affects cotreatment, increases expression	1
sulforaphane	decreases expression	1
cupric chloride	decreases expression	1
nickel sulfate	decreases expression	1
coumarin	decreases phosphorylation	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Arsenic	decreases expression, increases abundance	1
Azathioprine	decreases expression	1
Cadmium	increases abundance, increases expression	1
Carbamazepine	affects expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.